About efanesoctocog alfa
Extended half-life factor VIII replacement
Used for
- Prevention and treatment of bleeding in haemophilia A
- Bleeding control around surgery in haemophilia A
Usual adult dose
Prophylaxis: 50 IU/kg intravenously once weekly. Bleeding and surgery doses depend on severity and clinical response.
Usual dose in children
Prophylaxis: 50 IU/kg intravenously once weekly. Bleeding and surgery doses depend on severity and clinical response.
Common side effects
- Headache
- Joint pain
- Back pain
- Injection-site reactions
Important warnings
- Allergic reactions can occur, including severe hypersensitivity.
- Inhibitory antibodies to factor VIII may develop and reduce treatment response.
- Use with specialist monitoring; dose depends on bleeding severity and clinical response.
- This medicine is not for treating von Willebrand disease.
Pregnancy
Human pregnancy data are limited. Use only when clinically needed, under specialist guidance.
Breastfeeding
It is unknown whether efanesoctocog alfa passes into breast milk. Discuss use with a healthcare professional.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.